Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Verstovsek, Srdan; A Mesa, Ruben; Gotlib, Jason; S Levy, Richard; Gupta, Vikas; F DiPersio, John; V Catalano, John; W N Deininger, Michael; B Miller, Carole; T Silver, Richard; Talpaz, Moshe; F Winton, Elliott; H Harvey, Jimmie; O Arcasoy, Murat; O Hexner, Elizabeth; M Lyons, Roger; Paquette, Ronald; Raza, Azra; Vaddi, Kris; Erickson-Viitanen, Susan; Sun, William; Sandor, Victor; M Kantarjian, Hagop

doi:10.3324/haematol.2013.092155

Public

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Shared by NobleBlocks on Dec 1, 2013 • 12:00 AM UTC

Authors:

Srdan Verstovsek

Ruben A Mesa

Jason Gotlib

Abstract

COMFORT-I is a randomized, double-blind, placebo-controlled trial of the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib in 309 patients with intermediate-2 or high-risk myelofibrosis. This analysis of COMFORT-I describes the long-term efficacy and safety of ruxolitinib (median follow-up, 2 year...

Discussions